Advancements in HEFREF Management

This chapter explores the treatment of heart failure with reduced ejection fraction (HEFREF), focusing on ivabradine and vericiguat, including their mechanisms and clinical trial results. It emphasizes the necessity of guideline-directed medical therapy and optimizing patient conditions prior to surgical interventions. The discussion also highlights the need for personalized treatment approaches and the role of nutrition in managing heart failure symptoms.